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Forward genetic screens have been used as a powerful strategy to dissect complex biological pathways in many model
systems. A significant limitation of this approach has been the time-consuming and costly process of positional cloning
and molecular characterization of the mutations isolated in these screens. Here, the authors describe a strategy using
microarray hybridizations to facilitate positional cloning. This method relies on the fact that premature stop codons
(i.e., nonsense mutations) constitute a frequent class of mutations isolated in screens and that nonsense mutant
messenger RNAs are efficiently degraded by the conserved nonsense-mediated decay pathway. They validate this
strategy by identifying two previously uncharacterized mutations: (1) tom-1, a mutation found in a forward genetic
screen for enhanced acetylcholine secretion in Caenorhabditis elegans, and (2) an apparently spontaneous mutation in
the hif-1 transcription factor gene. They further demonstrate the broad applicability of this strategy using other known
mutants in C. elegans, Arabidopsis, and mouse. Characterization of tom-1 mutants suggests that TOM-1, the C. elegans
ortholog of mammalian tomosyn, functions as an endogenous inhibitor of neurotransmitter secretion. These results
also suggest that microarray hybridizations have the potential to significantly reduce the time and effort required for
positional cloning.
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Introduction
Forward genetic screens have been traditionally utilized in
model systems (e.g., Caenorhabditis elegans, Drosophila, yeast, and
Arabidopsis). More recently, large-scale screens have been
undertaken in vertebrate systems such as zebraﬁsh [1,2] and
mouse [3–5]. Mutations isolated in genetic screens are
typically identiﬁed by positional cloning. The difﬁculty posed
by positional cloning is determined by the size of the genome,
the recombination rate, and the difﬁculty of assessing the
mutant phenotype. For example, the mouse genome com-
prises 3,600 centimorgans (cM) and 3 3 10
9 base pairs. The
ultimate goal of a typical positional cloning project is to
analyze a sufﬁcient number of recombinants to map the
mutation to a small genetic interval (typically approximately
0.1 cM). Once a mutation has been precisely mapped, gene
identiﬁcation is typically achieved by a variety of strategies:
direct sequencing of the region (100 kb in the mouse),
candidate gene testing, or screening for informative alleles
(e.g., microdeletions). The difﬁculty of a particular positional
cloning can be compounded by the nature of the mutant
phenotype. This problem is particularly acute for behavioral
mutants, which often have phenotypes that must be scored in
multiple trials, or in populations of animals. Together, these
issues conspire to make traditional positional cloning a
signiﬁcant and costly bottleneck.
To circumvent these difﬁculties, several new technologies
have been developed to isolate mutations by reverse genetics.
Reverse genetic strategies include use of insertional mutagens
[6 10], PCR screens for randomly induced deletions [11],
homologous gene targeting [12,13], and physical or genetic
detection of point mutations in sequenced genes [14,15].
While reverse genetic strategies circumvent the positional
cloning bottleneck, these approaches also have limitations.
Mutations isolated by reverse genetics often lack obvious
phenotypic defects (e.g., because they are in functionally
redundant genes). Phenotypic differences observed in mu-
tants isolated by reverse genetics can be confounded by other
mutations in the genetic background, particularly since
animals are typically heavily mutagenized in these strategies.
For these reasons, it would be useful to develop methods that
would allow more rapid characterization of mutations
isolated in forward genetic screens.
We wondered whether microarray expression data could
facilitate the identiﬁcation of mutations responsible for
behavioral defects isolated in forward genetic screens. It is
well established that nonsense mutations result in the
degradation of the mutant messenger RNA (mRNA) via the
nonsense-mediated decay (NMD) pathway. A surveillance
mechanism common to all eukaryotes, NMD serves as a
quality control system to destroy faulty mRNAs whose
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protein [16 18]. NMD protects cells by eliminating inactive
or potentially deleterious dominant negative proteins that
are the result of somatic mutation, transcriptional mistakes,
or splicing errors.
It has been proposed that NMD could be used as a basis to
identify nonsense mutations in cell lines [19,20]. In principle,
a nonsense mutation in mutant animals could be identiﬁed
using microarray hybridizations to ﬁnd transcripts with
decreased abundance. In practice, microarray data alone
are unlikely to be sufﬁcient to identify nonsense mutations.
In addition to the expected statistical noise associated with
microarray experiments, there are likely to be transcriptional
changes in other genes that are caused by the mutation being
studied. The most powerful cloning approach would thus be
one that uses microarray data together with traditional
mapping information. Here, we present evidence supporting
the feasibility and general utility of this strategy.
Results
To test the feasibility of using microarrays to facilitate
positional cloning, we will address four questions. (1) How
frequently are nonsense alleles recovered in forward genetic
screens? (2) Are microarray hybridizations sensitive enough
to detect the decreased abundance of a nonsense mutant
transcript? (3) Can microarray hybridizations be used to
identify an uncloned behavioral mutant in C. elegans? (4) Is
this microarray-based strategy applicable to other model
organisms?
Nonsense Alleles Represent a Large Fraction of C. elegans
Mutations
The utility of microarrays in cloning depends on the
frequency with which nonsense alleles are recovered in
phenotypic screens. Since 15 of the 61 amino acid–encoding
codons are mutable to stop codons by a single base-pair
substitution, nonsense alleles are likely to represent a large
fraction of all alleles recovered after random mutagenesis
with agents that increase the rate of nucleotide misincorpo-
ration. To assess the prevalence of nonsense alleles isolated
following random mutagenesis, we compiled a list of
sequenced C. elegans mutant alleles by downloading informa-
tion from WormBase and conducting targeted literature
searches (Figure 1; Table S1). We focused on misincorpora-
tion mutations because these represent the most common
lesion caused by alkylating agents such as ethyl methane
sulfonate or N-ethyl-N-nitrosourea. In total, we examined 943
single-nucleotide-substitution loss-of-function alleles in 246
genes, which were published by 99 laboratories. We then
classiﬁed these alleles as putative NMD targets (nonsense) or
non-NMD targets (missense). We found that 41% of the
alleles were putative NMD targets. Interestingly, this ﬁgure is
comparable to estimates that one-third of human genetic
diseases are the result of nonsense mutations [21,22].
We calculated the percentage of nonsense alleles recovered
for each of the 117 genes in our dataset with three or more
characterized alleles (Figure 1). For 20% of these genes, no
nonsense alleles have been identiﬁed, even in cases where ten
alleles are known. Many of these genes are known to cause a
lethal phenotype as a null mutation (e.g., acy-1, unc-17, and let-
502). Since many screens demand homozygous viable pheno-
types, it is not surprising that nonsense alleles were rarely
recovered in these genes. For another 20% of these genes, all
known alleles are nonsense mutations. These might comprise
genes for which mutant phenotypes are expressed only when
gene function is completely eliminated. For all other genes,
there appears to be a broad distribution in the fraction of
nonsense alleles recovered, with a mode occurring at 40%
nonsense alleles. Thus, while a high frequency of nonsense
alleles seems to be a general feature common to many screens
in C. elegans, this is likely to vary considerably for different
gene classes.
Proof of Principle: mec-3 and unc-43 CaMKII Mutations Are
Detectable by Microarray
Are microarray hybridizations sensitive enough to detect
changes in mutant transcript abundance due to a nonsense
lesion above the global variation in gene expression between
Figure 1. Fraction of C. elegans Alleles That Are Nonsense Mutations
Molecular information about alleles was obtained from WormBase and
literature searches. Graph includes 117 genes for which molecular
characterization of three or more alleles was available (770 alleles total).
Of these 117 alleles, 22 (19%) have no known nonsense mutations. Many
of these no-nonsense alleles are in genes that are required for viability.
DOI: 10.1371/journal.pgen.0010002.g001
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Synopsis
Genetic screens are commonly used to figure out which genes are
involved in a biological process. The first step in a genetic screen is
to isolate mutant animals that are defective in the process being
studied. The next step is to find which of the thousands of genes has
the mutation that causes the observed defect. Positional cloning,
the tried-and-true method for locating mutations, is slow and
expensive. The authors propose using microarray hybridizations to
speed the process. Their approach relies on the fact that a large
fraction of the mutations found in screens are the results of
premature stop codons, a particularly severe type of mutation. In
cells, messages containing premature stop codons are rapidly
destroyed by a protective pathway, called nonsense-mediated
decay, thus making them directly detectable by microarray hybrid-
ization.
The authors apply this strategy retrospectively to known mutants in
Caenorhabditis elegans, Arabidopsis, and mouse. They identify two
uncharacterized mutations in C. elegans, including one, tom-1, found
in a forward genetic screen for enhancers of neurotransmission.
Interestingly, their characterization of tom-1 mutants suggests that
the highly conserved protein tomosyn inhibits neurotransmission in
neurons. This study shows that microarray hybridizations will help
reduce the time and effort required for positional cloning.mutant and control strains? Some potential sources of
variance in gene expression include random ﬂuctuations in
gene expression [23,24], uncontrolled differences between the
mutant and control populations (e.g., differences in devel-
opmental stage or physiological status), and differences in
genetic backgrounds [25,26]. Perhaps the most important
potential limitation is changes in gene expression that are a
secondary consequence of a mutation. This could be
particularly problematic for mutations in genes encoding
transcription factors or other components of signal trans-
duction cascades, the loss of which would be expected to alter
the expression of many downstream genes.
To address some of these concerns, we examined the large
collection of microarray experiments used to build a whole-
genome expression proﬁle for C. elegans [27]. Most of these
experiments, which were done with printed microarrays,
were designed to identify gene-expression proﬁles associated
with various developmental programs or speciﬁc tissues.
However, one set of experiments analyzed changes in gene
expression in mutants lacking the MEC-3 transcription factor
(see Materials and Methods) [28]. The mec-3(e1338) allele
corresponds to a W69Stop mutation, and homozygous
animals carrying this mutation are touch-insensitive [29,30].
Using this dataset, we classiﬁed genes as differentially
expressed in mec-3(e1338) based on two criteria: average fold-
change in expression level and statistical signiﬁcance using a
Student’s t-test. We constructed a volcano plot with the
log2(fold-change) on the x-axis and negative log10(p-value) on
the y-axis [31]. This provides a useful way to visualize
differentially expressed genes—those whose expression level
is down (negative on the x-axis) and that show high statistical
s i g n i ﬁ c a n c e( l a r g eo nt h ey-axis). Seventy genes were
identiﬁed as having signiﬁcantly reduced expression in mec-
3(e1338), using fold-change greater than 1.0 (log2 scale) and p
, 0.01 as thresholds for decreased expression (Figure 2). Had
e1338 been an uncharacterized mutation that we were
attempting to clone, the next step would be to narrow the
candidate list of 70 genes using mapping data. Fifteen of these
genes are on Chromosome 4, which contains mec-3 and
approximately 2,900 other genes. Of these, only three
differentially expressed genes fall within a two-map-unit
interval spanning mec-3 and approximately 100 other genes.
Thus, even in the case of a transcription factor, microarray
hybridizations are sufﬁciently sensitive to detect changes in
the mutant mRNA abundance despite broader changes in
gene expression. In the case of MEC-3, it is likely that the
reduced abundance of e1338 mRNA is due both to NMD and
to positive autoregulation of mec-3 transcription [32]. There-
fore, triangulating between rough mapping information and
microarray data would have facilitated the rapid cloning of
mec-3.
To further address the sensitivity of microarray-assisted
cloning, we analyzed changes in gene expression observed in
KP3365 unc-43(n1186) mutants. The unc-43 gene encodes type
II calcium- and calmodulin-dependent protein kinase (CaM-
KII), which is broadly expressed in the worm nervous system
as well as in muscles and in the intestine [33]. This provides
another demanding test case because CaMKII plays a pivotal
role in calcium-mediated signaling in neurons, and unc-43
mutations are known to cause changes in the expression of
other genes [34]. The n1186 allele corresponds to a Q67Stop
mutation, and homozygous animals carrying this mutation
have relatively subtle behavioral defects [33].
We hybridized total RNA isolated from wild-type and
KP3365 unc-43(n1186) CaMKII mutant animals to the Affyme-
trix C. elegans GeneChip (Dataset S1). Using fold-changes
greater than 0.5 (log2 scale) and p , 0.01 as thresholds, we
found 20 probesets with decreased expression in KP3365 unc-
43(n1186) CaMKII mutants as compared to wild-type controls
(Figure 3). Eight of these probesets correspond to sequences
on Chromosome 4, which contains unc-43 CaMKII and
approximately 2,900 other genes. Strikingly, seven of these
eight probesets correspond to the unc-43 gene. These seven
probesets correspond to nonoverlapping regions of the
coding sequence, as well as the 59 and 39 untranslated region
of unc-43 (Figure S1). Only two of these probesets
(193459_s_at and 193463_s_at) were annotated as corre-
sponding to the unc-43 CaMKII mRNA transcript according
to the annotation of the C. elegans GeneChip provided by
Affymetrix (downloadable at http://www.affymetrix.com).
During our examination of the eight candidate probesets
that showed decreased expression and were on Chromosome
4, we discovered the ﬁve additional probesets that corre-
sponded to unc-43 CaMKII. These additional probesets
provided a serendipitous blind control, since we were not
aware of their existence until they appeared on our candidate
list from the hybridization. This redundancy in probes is a
result of overlap in the various databases used to design the
GeneChip and inaccuracies in gene predications at the time
of design (December 2000). Approximately 2,400 (13%) of the
genes on the C. elegans GeneChip are represented by multiple
probes. While it is unusual to have seven probesets on a
microarray corresponding to a single gene, this illustrates the
robustness of our ability to measure the changes in
Figure 2. Analysis of mRNA Abundance in mec-3(e1338) Animals
Fold-change (x-axis) is plotted against the statistical significance (y-axis)
for each probeset. Fold-changes are shown on log2 scale. p-Values are
shown on a negative log10 scale. The symbol 3 indicates genes with
reduced expression in mec-3(e1338) animals (fold-change ,  1, p ,
0.01). Light blue circles indicate genes with reduced expression that are
also on Chromosome 4. Dark blue circles indicate genes with reduced
expression that are within 1 cM to the left or right of mec-3. The open red
circle indicates the mec-3 gene.
DOI: 10.1371/journal.pgen.0010002.g002
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Microarray-Assisted Cloningexpression of unc-43 CaMKII. This demonstrates that micro-
array hybridizations can be used to measure the decrease in
unc-43 transcript in the unc-43(n1186) mutant. These results
also suggest that microarray hybridizations utilizing printed
arrays and those utilizing Affymetrix chips are both sufﬁ-
ciently sensitive to detect changes in the abundance of
mutant mRNAs, even in the relatively stringent cases of
transcription factors and signal transduction components.
Identification of a hif-1 Polymorphism in the KP3365 Strain
One potential limitation of our strategy is that mutant
strains may contain multiple mutations, some of which do not
contribute to the mutant phenotype. This will be particularly
true in heavily mutagenized strains, and in cases where the
mutants have not been extensively backcrossed with wild-type
strains. Therefore, we examined the KP3365 unc-43(n1186)
CaMKII hybridization data for other genes with signiﬁcantly
reduced expression. Interestingly, the gene with the largest
decrease in expression in KP3365 unc-43(n1186) animals was
not unc-43; rather, it was hif-1 (Figure 3), which encodes the
worm ortholog of hypoxia-inducible factor 1a, a transcrip-
tion factor that mediates transcriptional responses to oxygen
deprivation [35]. This is the only probe corresponding to hif-1
on the C. elegans GeneChip. There are two likely explanations
for the observed decrease in hif-1 transcript levels: either hif-1
expression is regulated by unc-43 CaMKII, or the KP3365
strain contains a loss-of-function polymorphism in the hif-1
gene. Sequencing genomic DNA from KP3365 animals
revealed two mutations in the last exon of hif-1 (nu469)
(Figure 4A). Since neither of these mutations results in a
premature stop, why is transcript level decreased? To address
this issue, we sequenced hif-1 cDNA made from wild-type and
KP3365 animals. This revealed that the nu469 mutations
cause an aberrant splicing of the hif-1 mRNA, removing 135
base pairs from the last exon (Figure 4A). We conﬁrmed this
change in hif-1 splicing by RT-PCR (Figure 4B). The
aberrantly spliced hif-1(nu469) transcript is likely to have
reduced stability.
In aerobic conditions, the HIF-1 protein is constitutively
degraded by the von Hippel–Lindau ubiquitin ligase [36–38];
consequently, the hif-1(nu469) mutation would presumably be
phenotypically silent in normal growth conditions. The hif-
1(nu469) mutation was not present in several other strains
containing the unc-43(n1186) allele, suggesting that this
mutation occurred spontaneously during culturing in our
laboratory (data not shown). In summary, KP3365 animals
carry a previously uncharacterized polymorphism in hif-1,
which we identiﬁed based solely on our microarray hybrid-
ization results. Identifying such polymorphisms may allow
researchers to explain unexpected aspects of mutant pheno-
types of particular strains.
Using Microarrays to Identify a Mutation in Tomosyn, an
Inhibitor of Neurotransmitter Secretion
To further address whether microarray hybridizations can
be used to identify uncharacterized mutations, we analyzed a
behavioral mutant that was isolated in a forward genetic
screen for inhibitors of neurotransmitter secretion. Neuro-
transmission serves as the primary mode of communication
between cells in the nervous system. Neurotransmitters such
as acetylcholine (ACh) are secreted by presynaptic nerve cells,
and activate receptors on postsynaptic cells. Behavioral and
pharmacological screens in C. elegans have proven to be a
powerful approach to identifying molecules involved in
synaptic transmission and nervous system function [39–42].
The cholinesterase inhibitor aldicarb is widely used as a
means to monitor ACh secretion at the C. elegans neuro-
muscular junction [41,43–46]. In the presence of aldicarb,
ACh accumulates in the synaptic cleft, causing the body wall
muscles to become hypercontracted and animals to become
paralyzed. Mutations that increase ACh secretion cause
hypersensitivity to the paralytic effects of aldicarb [46–48].
To identify negative regulators of ACh secretion, we used
hypersensitivity to aldicarb as the basis for a forward genetic
screen. One of the strongest mutations recovered in our
screen was nu468 (ﬁlled squares in Figure 5).
We meiotically mapped nu468 to Chromosome 1, which
contains approximately 2,700 genes. We then hybridized RNA
from KP3293 nu468 animals to the C. elegans GeneChip,
comparing the hybridizations to wild-type hybridizations as
previously described (Dataset S1). Six probesets showed
signiﬁcantly decreased expression in KP3293 animals (fold-
change ,  0.5, p , 0.01) (Figure 6), of which two
corresponded to genes on Chromosome 1. Sequencing DNA
from the mutant revealed a nonsense mutation in one of
these genes, tom-1, the C. elegans ortholog of mammalian
tomosyn (Figures 7A and S2). This lesion, a predicted NMD
target, is consistent with the decreased transcript levels that
we observed by the microarray hybridization. This is the only
probe corresponding to tom-1 on the C. elegans GeneChip.
We performed several experiments to conﬁrm that the tom-
1(nu468) mutation caused the aldicarb hypersensitivity
observed in the KP3293 strain. First, we tested a second tom-
1 allele, ok285, which was generated by the C. elegans Gene
Knockout Consortium (http://celeganskoconsortium.omrf.
org). This allele, tom-1(ok285), encodes a mutant protein
lacking 202 residues in a highly conserved region, and
Figure 3. Analysis of mRNA Abundance in the KP3365 unc-43(n1186)
CaMKII Strain
Expression data are illustrated as described in Figure 2. The symbol 3
indicates probesets with reduced expression in KP3365 animals (fold-
change ,  0.5, p , 0.01). Filled blue circles indicate probesets with
reduced expression that are also on Chromosome 4. Open red circles
indicate probesets corresponding to the unc-43 CaMKII gene. The black
square indicates the probeset corresponding to the hif-1 gene.
DOI: 10.1371/journal.pgen.0010002.g003
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Microarray-Assisted Cloninghomozygous tom-1(ok285) mutants exhibited aldicarb hyper-
sensitivity similar to that observed in KP3293 tom-1(nu468)
mutants (triangles in Figure 5). Second, the aldicarb hyper-
sensitivity of KP3293 tom-1(nu468) animals was rescued by a
transgene driving expression of a tom-1 cDNA in cholinergic
neurons (open circles in Figure 5). Third, we found that a 4.2-
kb tom-1 promoter fragment was sufﬁcient to drive expression
of green ﬂuorescent protein in the ventral cord motor
neurons (Figure 7B), consistent with the idea that tomosyn
acts as an inhibitor of ACh secretion in motor neurons.
Tomosyn also showed expression in several neurons in head
(Figure 7C) and tail ganglia (Figure 7D).
Tomosyn is an approximately 1,100–amino acid protein
with two functional domains: (1) the C-terminal coiled-coil
domain, which shares homology with synaptobrevin and has
been shown to bind to syntaxin and SNAP-25, and (2) the
approximately 600-residue WD40-rich N-terminal region,
which shows strong homology to the ﬂy tumor suppressor
protein Lethal giant larvae (Figure 7A) [49,50]. Previous
studies have shown that the synaptobrevin-like coiled-coil
domain of rat tomosyn binds syntaxin and SNAP-25, forming
a SNARE-like complex that occludes synaptobrevin [51]. This
suggests a mechanism whereby tomosyn competitively inhib-
its secretion by preventing SNARE complex formation.
Supporting this hypothesis, overexpression of tomosyn in
neuroendocrine cells results in a decrease in exocytosis in
response to depolarization [49–52]. While these overexpres-
sion studies show that tomosyn can function to inhibit dense
core vesicle release, they do not address the endogenous
function of tomosyn. Our results provide the ﬁrst in vivo
evidence suggesting that endogenously expressed tomosyn
inhibits neurotransmitter secretion in neurons.
Generalizability of Microarray-Assisted Cloning
Since NMD functions in all eukaryotes [16,18], we
wondered whether our strategy could be applied to other
model systems. To address this, we conducted a retrospective
analysis of microarray data from mutants in other organisms.
We searched the public microarray databases for experiments
in which researchers had analyzed mutants in other organ-
isms. Speciﬁcally, we looked for hybridizations where mutant
RNA had been compared to wild-type RNA and where the
mutation was the result of a premature stop codon (and thus
a predicted NMD target). For practical reasons, we also
Figure 4. Characterization of the Splicing Defect in hif-1(nu469)
(A) Diagram of hif-1 gene structure and the two mutations in hif-1(nu469), a previously uncharacterized lesion in the background of the KP3365 strain.
This lesion consists of two closely linked mutations: (1) C!A at position 2315 of the coding sequence, resulting in a P771Q mutation, and (2) an
insertion of TTATCA after position 2373. Sequencing cDNA from KP3365 revealed that these two mutations result in the inappropriate splicing of the
hif-1 transcript (indicated by a dashed line), removing 135 base pairs of the last exon. Location of primers for PCR are indicated by half-arrows above
exons 9 and 11.
(B) RT-PCR confirmed the altered splicing of the hif-1(nu469) mRNA.
DOI: 10.1371/journal.pgen.0010002.g004
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Microarray-Assisted Cloningrequired that the mutant gene be represented and detectable
on the microarray. Surprisingly, we found that only two
experiments met these criteria. The ﬁrst was a study of pmr4
(powdery mildew resistant 4), a cell-wall biosynthesis gene in
Arabidopsis that confers pathogen resistance when mutated.
The lesion used in the microarray studies was a premature
stop codon in the second exon (PMR4 dataset) [53]. The
second was a study of the mdx mouse, an animal model of
Duchenne muscular dystrophy, with a premature stop codon
in exon 23 of dystrophin (MDX dataset) [54,55]. In both of
these studies, the authors knew the nature of the mutation
and were attempting to ﬁnd genes whose expression changed
in the mutant background.
For these two examples, we asked retrospectively whether
hybridization data would have aided identiﬁcation of the
mutant genes. To do this, we reanalyzed the PMR4 and MDX
data as described for the C. elegans mutants and constructed
volcano plots (Figure 8). Each of these datasets had a different
distribution on the fold-change and signiﬁcance axes because
of differences in the sample preparation, labeling efﬁciency,
type of GeneChip, and number of hybridizations. We there-
fore adjusted our signiﬁcance and ratio thresholds for
differential expression (see Materials and Methods). In the
Figure 5. Aldicarb Sensitivity and Rescue of KP3293 nu468
Levels of ACh secretion were assayed by following the time course of
paralysis of animals on 1 mM aldicarb. Filled circle, wild-type; filled
square, nu468, mutant recovered in our screen; filled triangle, ok285
deletion allele of tom-1; open circle, nu468 with a transgene expressing
tom-1 cDNA under the unc-17 promoter. Data shown are averages from
seven trials, except for ok285, which is an average of five trials. Error bars
represent standard error.
DOI: 10.1371/journal.pgen.0010002.g005
Figure 6. Positional Cloning of tom-1(nu468)
Expression data are illustrated as described in Figure 2. The symbol 3
indicates probesets with reduced expression in KP3293 nu468 (fold-
change ,  0.5, p , 0.01). Filled blue circles indicate probesets with
reduced expression in KP3293 nu468 that are also on Chromosome 1.
The open red circle indicates the probeset corresponding to tom-1.
Sequencing of the tom-1 gene in KP3293 nu468 revealed a W212Stop
mutation in the tom-1 gene (see Figure 7A).
DOI: 10.1371/journal.pgen.0010002.g006
Figure 7. Expression of TOM-1, the C. elegans Ortholog of Tomosyn
(A) Schematic of worm tomosyn indicating the location of the premature
stop found in nu468 and deletion in ok285.
(B–D) Expression pattern of tom-1 characterized with 4.2 kb of sequence
upstream of the start codon driving expression of green fluorescent
protein. Expression is seen in ventral cord motor neurons, with cell
bodies indicated by arrowheads (B) and a number of neurons in the head
(C) and the tail (D). Scale bars = 10 lm.
DOI: 10.1371/journal.pgen.0010002.g007
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Microarray-Assisted CloningPMR4 hybridizations, 17 genes showed signiﬁcantly decreased
expression (fold-change , 1.0, p , 0.01). Of these, two genes
were on Chromosome 4, the most signiﬁcant of which was
PMR4 (Figure 8A). In the case of the MDX data, 22 genes
showed signiﬁcantly decreased expression (fold-change ,
 1.5, p , 0.0001). Of these, only the dystrophin gene was on X
(Figure 8B). In each case, there was only one probe on the
GeneChip corresponding to the mutant gene. For both of
these examples, the combination of microarray data and
chromosomal mapping quickly reduced the number of
candidates to one or two genes.
Discussion
We present evidence demonstrating the utility of micro-
array hybridizations in facilitating the rapid identiﬁcation of
mutations isolated in forward genetic screens. Several results
suggest that this technique will be widely applicable. This
strategy was successful in identiﬁcation of C. elegans, mouse,
and Arabidopsis mutations. Mutations were successfully iden-
tiﬁed in both transcription factors and signal transduction
components, which are likely to be the most challenging
cases. Mutant genes were successfully detected using data
obtained with both printed arrays and Affymetrix chips. And
ﬁnally, we were able to identify two previously uncharac-
terized C. elegans mutations with this approach.
Will this strategy work for genes that regulate the
expression of many other genes? We provide examples for
successful identiﬁcation of three genes that directly affect
transcription—two transcription factors (mec-3 and hif-1) and
a protein kinase that regulates neuronal gene expression (unc-
43). Although 70 genes were differentially expressed in mec-3
mutants, only three differentially expressed genes mapped
within a 2-cM interval containing mec-3 and 100 other genes.
Therefore, microarray hybridizations would have facilitated
identiﬁcation of mec-3.
The success rate for this strategy depends on three factors:
(1) the fraction of genes that are detectable by microarray, (2)
the frequency of nonsense alleles recovered in screens, and
(3) the efﬁciency with which nonsense mutated mRNAs are
degraded by NMD. In our hybridizations using mRNA
prepared from whole worms, 80% of the genes on the array
showed detectable expression. In cases where a mutation
affects a particular cell type or tissue, the likelihood of
detecting a particular transcript can be increased using RNA
isolated from that tissue or cell type [28,56].
What fraction of newly isolated mutations will be nonsense
alleles (see Figure 1)? Our analysis suggests that for 20% of C.
elegans genes, nonsense mutations are rarely recovered. For
the remaining 80% of C. elegans genes, 45% of alleles
recovered were nonsense alleles. Given these ratios, the rate
of successful gene identiﬁcation by microarray hybridization
could be increased by analyzing multiple alleles of the same
gene and by selecting genes for which null alleles are the most
frequently isolated class of alleles recovered in screens.
Furthermore, microarray-assisted cloning will likely be useful
for other categories of alleles that decrease transcript
abundance, e.g., the spontaneous hif-1(nu469) mutation. These
include mutations altering pre-mRNA splicing, mutations in
promoters, frameshift mutations, and mutations yielding
transcripts that lack termination codons [57–59].
What fraction of nonsense alleles are efﬁciently targeted by
the NMD machinery? In each of the six examples we present
above, this was the case, but how often do nonsense
transcripts evade degradation by the NMD machinery? Rules
governing NMD recognition of mutant mRNAs have been
described in yeast, C. elegans, and mammals [16–18,59–63]. The
NMD machinery distinguishes premature stop codons from
natural stops using the exon-junction complexes that are
deposited at exon–exon boundaries by the spliceosome. Stops
that are greater than 50–55 base pairs upstream of the last
exon-junction complex are recognized by the NMD machi-
nery as premature and are efﬁciently targeted for destruction
[61,64]. Prior studies have shown that 100% (n = 23) of C.
elegans nonsense mutations were susceptible to NMD surveil-
lance (measured either by mRNA abundance or by suppres-
sion of mutant phenotypes by NMD pathway mutations) [17].
Of these, six mutations (26%) were judged to be only partially
targeted by NMD. Based on these examples and those we
describe here, we estimate that 75%–100% of nonsense
alleles in C. elegans would show a detectable decrease in mRNA
Figure 8. Analysis of Nonsense Mutants in Arabidopsis and Mouse
(A) PMR4 mutant; (B) MDX mutant. Expression data are illustrated as described in Figure 2. The symbol3indicates probesets with reduced expression in
the nonsense mutant (fold-change ,  1.0, p , 0.01) for PMR4 and (fold-change ,  1.5, p , 0.0001) for MDX. Numbers of genes with significantly
reduced expression are indicated for both mutants. Filled blue circles indicate probesets with reduced expression that are on same chromosome as the
mutant gene. The open red circle indicates the probeset corresponding to the mutant gene.
DOI: 10.1371/journal.pgen.0010002.g008
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by microarray, nonsense allele frequency, and NMD efﬁ-
ciency), we expect microarray-assisted cloning to be success-
ful in 25%–30% of positional clonings (assuming only one
allele is hybridized per gene).
The principal costs of positional cloning are those incurred
in isolating, phenotyping, and genotyping a sufﬁcient number
of recombinants (i.e., informative meioses) to map a mutation
to a small genetic interval. A typical positional cloning
requires 2,000–10,000 informative meioses. Our results
suggest that microarray hybridizations can signiﬁcantly
reduce the number of meioses required for positional
clonings. In ﬁve of six cases, microarray data in conjunction
with chromosomal linkage data were sufﬁcient for gene
identiﬁcation. Therefore, while we expect that this strategy
will be useful in many genetic systems, microarray-assisted
cloning promises to provide the greatest value in organisms
such as mouse and zebraﬁsh, where long generation times and
large genomes make meiotic mapping more time consuming
and costly. Furthermore, microarray-assisted cloning may be
particularly useful in cases where mutant phenotypes are
more difﬁcult to assess, such as behavioral mutants, or
incompletely penetrant or complex (i.e., multigenic) traits
[65,66]. Given the effort and challenges involved in meiotic
mapping and the relative ease and speed of microarray
hybridizations, we believe that this microarray-based strategy
provides signiﬁcant beneﬁt, even though it will be successful
in only a subset of cases.
Can microarrays be used to aid the cloning of human
disease genes? One-third of human disease genes are
predicted to be caused by nonsense lesions or mutations that
decrease transcript abundance [21,22]. Furthermore, non-
sense mutant transcripts encoded by disease genes such as
BRCA1 and hepatocyte nuclear factor 1a have been shown to be
effectively degraded by NMD [67,68]. Given the enormous
time and expense involved in mapping genes in humans, the
strategy described here could provide a valuable addition to
the toolbox of human geneticists.
Materials and Methods
Allele analysis. Information about 930 recessive single base-pair
substitution alleles was downloaded from WormBase (http://
www.wormbase.com), Release WS123 (see Table S1). Information
about 82 additional alleles was obtained through literature searches.
Based on their molecular description, 943 alleles were classiﬁed as
either NMD targets (nonsense) or non-NMD targets (missense).
Excluded from the analysis were 69 alleles that could not be
deﬁnitively classiﬁed. These alleles included those with incomplete
molecular descriptions and those with lesions such as splice site
mutations that could not be classiﬁed without further character-
ization.
RNA sample preparation. Animals analyzed in microarray experi-
ments were ﬁrst synchronized by hypochlorite treatment and
arrested at the ﬁrst larval stage by incubation for 22 h in M9
[27,69]. Animals were then grown at 20 8C on 15-cm NG HB101 plates
until the fourth larval stage (approximately 46 h). Animals were
washed, harvested in M9, and then ﬂash-frozen in liquid nitrogen and
stored at  80 8C. Total RNA was prepared by Trizol extraction
(Invitrogen, Carlsbad, California, United States).
Microarray target preparation and hybridization. Targets were
prepared and hybridized at the Harvard Medical School Biopolymer
Facility. Starting with 10 lg of total RNA, ﬁrst-strand cDNA was
synthesized as described in the Affymetrix (Santa Clara, California,
United States) expression technical manual. Brieﬂy, 10 lg of RNA was
added to 1 llo f5 0lM T7 primer (HPLC puriﬁed) (Integrated DNA
Technologies, Coralville, Iowa, United States) in a volume of 9 ll.
Then 1 ll of each Poly A spike control (5 nM) was added to the RNA,
and T7 was added as an internal control. Poly A spikes were created
from Poly A–tailed genes from Bacillus subtilis cloned into Stratagene
(La Jolla, California, United States) pBluescript as an XhoI-to-NotI
insert 59–39, respectively, and commercially available through ATCC
(Manassas, Virginia, United States) (see Affymetrix technical expres-
sion manual). The RNA, T7, and Poly A spike controls were heated to
70 8C for 10 min and then placed on ice for 5 min. The RNA, T7, and
Poly A mix was then heated to 42 8C. Then 4 llo f5 3 ﬁrst-strand
buffer (Invitrogen), 2 ll of 0.1 M DTT (Invitrogen), 1 llo f1 0m M
dNTP (Invitrogen), and 1 ll of Superscript II, RNase H was added to
the RNA and incubated at 42 8C for 1 h. Double-strand DNA was
created via a replacement reaction under the following conditions.
To the 20-ll ﬁrst-strand reaction was added 91 ll of water, 30 llo f
second-strand buffer (Invitrogen), 3 ll of 10 mM dNTP (Invitrogen),
1llo fEscherichia coli DNA ligase (Invitrogen), 1 ll of RNase H
(Invitrogen), and 4 llo fE. coli DNA polymerase (Invitrogen). This
130-ll second-strand mix was added to the ﬁrst-strand reaction and
incubated at 16 8C for 2 h, then 2 ll of T4 DNA polymerase was added
for 5 min at 16 8C, then the reaction was phenol-chloroform-
extracted using 150 ll of phenol chloroform isoamyl alcohol (pH 7)
(Ambion, Austin, Texas, United States), and the organic and aqueous
phases were separated using a 1.5-ml phase lock heavy gel
(Brinkmann Eppendorf, Westbury, New York, United States). The
150-ll aqueous layer was removed and precipitated in 375 ll of 100%
ethanol and 15 ll of 3 M sodium acetate (Sigma, St. Louis, Missouri,
United States). The cDNA pellet was isolated using an Eppendorf
(Hamburg, Germany) 5415C centrifuge at room temperature for 20
min. Ethanol was aspirated and the pellet washed in 75% ethanol,
centrifuged for 10 min, and aspirated. The cDNA pellet was
rehydrated using 22 ll of nuclease-free water (Ambion) and used
with the BioArray HighYield RNA Transcript Labeling Kit T7 (Enzo
Life Sciences, Farmingdale, New York, United States). The resulting
biotinylated cRNA probes were puriﬁed using RNeasy columns
(Qiagen, Valencia, California, United States) and quantitated using
A260 with an Agilent (Palo Alto, California, United States) 8453
spectrophotometer. Then 15 lg of labeled probe was fragmented with
53 fragmentation buffer (see Affymetrix technical manual) and
combined with hybridization controls (Affymetrix), herring sperm
DNA (Promega, Madison, Wisconsin, United States), and BSA
(Invitrogen) to create 300 ll of hybridization mix. Of this, 200 ll
was added to the Affymetrix C. elegans GeneChip. Hybridization was
done in a GeneChip Hybridization Oven 320 for 16 h at 45 8C,
processed on an Affymetrix Fluidics Station 400 using double
ampliﬁcation staining (see Affymetrix technical manual), and washed
using ﬂuidics protocol EukGE-WS2v4. The GeneChips were then
scanned on a Hewlett-Packard (Palo Alto, California, United States)
GeneArray Scanner.
Public datasets. Descriptions of all available hybridizations in the
C. elegans whole-genome expression proﬁles were downloaded from
the Stanford Microarray Database (http://genome-www5.stanford.
edu). These were then searched to ﬁnd direct mutant versus wild-
type comparisons. The 368 hybridizations that were publicly
accessible included a large number of developmental time courses,
aging experiments, and heat-shock and tissue-speciﬁc expression
proﬁles (see Figure 2 in [27] for more detail). The only direct mutant
versus wild-type comparison was the mec-3(e1338) analysis, which
consisted of six hybridizations. For these experiments, normalized log
expression ratios were downloaded from the Stanford Microarray
Database (ExptSetNo = 1461). Affymetrix expression values for
mouse and Arabidopsis datasets were downloaded from NCBI’s Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo).
Microarray data analysis. For Affymetrix data, probesets were ﬁrst
ﬁltered to eliminate those that showed no detectable signal. A
threshold of 32 was used for the C. elegans and Arabidopsis data. A
threshold of 256 was used for the mdx data because these data showed
signiﬁcantly higher signals than the other datasets. This is most likely
because the RNA for these experiments was prepared from a single
tissue (mouse skeletal muscle), as opposed to the C. elegans and
Arabidopsis RNA, which was derived from the whole organism. For
printed arrays, only spots that showed detectable signal (mean signals
greater than 1.5 standard deviations above background) were
included in the analysis.
Probes were classiﬁed as differentially expressed based on two
criteria: fold-change and statistical signiﬁcance. For Affymetrix data,
fold-change was calculated as the average expression in the mutant
divided by average expression in wild-type. For printed arrays (mec-3),
fold-change was calculated by averaging the expression ratio in each
of the mutant–versus–wild-type replicate hybridizations. This ratio
provides a measure of the magnitude of expression difference
between mutant and wild-type samples. To assess the statistical
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expression values in the mutant hybridizations to replicate expres-
sion values in the wild-type hybridizations using a Student’s t-test,
and calculated a p-value. We then constructed a volcano plot with the
log2(fold-change) on the x-axis and negative log10(p-value) on the y-
axis [31]. Cutoffs for differential expression were based on shape and
distribution of individual volcano plots.
Raw image ﬁles were converted to probeset data (.cel ﬁles) in
Microarray Suite (MAS 5.0). The nine probeset data ﬁles were
normalized together and expression values were determined using
the Robust Multi-chip Average (RMA) method as implemented in
RMA Express (http://stat-www.berkeley.edu/;bolstad/RMAExpress/
RMAExpress.html). Subsequent analysis was done using the R
statistical computing package (http://www.r-project.org) and the
Bioconductor libraries (http://www.bioconductor.org). Graphs were
produced in Igor Pro 4.0 (WaveMetrics, Lake Oswego, Oregon,
United States). Probeset annotations were downloaded from the
Affymetrix Web site (http://www.affymetrix.com).
Molecular characterization of hif-1(nu469). Using RNA prepared
from KP3365 and wild-type animals, ﬁrst-strand cDNA was synthe-
sized using a primer speciﬁc for the 39 UTR of hif-1 (Invitrogen). The
hif-1 gene was then ampliﬁed by PCR from this cDNA and sequenced.
Isolation and mapping of the tom-1 mutation. The tom-1(nu468)
allele was isolated in an ethyl methane sulfonate screen for mutants
that displayed hypersensitivity to aldicarb. F2 progeny of mutagen-
ized animal were transferred to agar plates containing 0.5 mM
aldicarb (Chem Service, West Chester, Pennsylvania, United States).
After 1 h, a time point at which all wild-type worms were still moving,
paralyzed animals were transferred to separate plates and rescreened
for aldicarb sensitivity in subsequent generations. nu468 was
determined to be recessive and was mapped to Chromosome 1 using
conventional meiotic mapping.
Analysis of aldicarb sensitivity. Aldicarb sensitivity was assessed
essentially as described [45,46]. Brieﬂy, for each experiment, 20 to 25
animals were transferred to agar plates containing 1 mM aldicarb
(Chem Service). Paralysis was assessed every 10 min by prodding each
animal with a platinum wire. Data from independent trials were
averaged and used to calculate standard error. All experiments were
conducted blind with respect to the genotype of the animals.
Molecular characterization of tom-1(ok285). Genomic sequence
from VC223 animals, available on WormBase, shows a deletion of
1,580 nucleotides that removes all of exons 11–13 and part of exon
10. To characterize the effect of this lesion on the tom-1 gene product,
we puriﬁed RNA from VC223 animals and ampliﬁed the mutated tom-
1 mRNA by RT-PCR (Invitrogen). Sequencing revealed that the
genomic deletion results in an in-frame lesion in the mRNA,
removing 606 nucleotides of coding sequence, and adding 23
nucleotides of intronic sequence and a 490-base-pair alternative
exon from isoform C of tom-1 that is located just downstream of the
deletion.
Rescue of tom-1(nu468). tom-1(nu468) was rescued using the full-
length cDNA of the major splice form of tom-1 (M01A10.2a) under the
promoter of unc-17 synaptic vesicle ACh transporter. A transgenic
strain was isolated by microinjecting the rescuing plasmid at 100 ng/ll
using pttx-3::dsRed as a marker into nu468. During characterization
and rescue of tom-1, we discovered that the start site and ﬁrst exon
were incorrectly predicted and described in WormBase. We
identiﬁed the correct start site and initial two exons of tom-1 by
performing RT-PCR using a primer complementary to the trans-
splice acceptor (SL1). This corrected version of tom-1 shows much
better alignment to the N-terminus of mammalian homologs (see
Figure S2).
Supporting Information
Dataset S1. Microarray Expression Data from Wild-Type, unc-
43(n1186), and tom-1(nu468) Animals
Found at DOI: 10.1371/journal.pgen.0010002.sd001 (2 MB TDS).
Figure S1. Probeset Alignments to unc-43 CaMKII Isoform H
(K11E8.1h)
Target sequences were downloaded (http://www.affymetrix.com) and
aligned to unc-43 CaMKII isoform H. Since a majority of genes on the
C. elegans GeneChip are represented by one probeset, unc-43
represents an atypica1 case. To explain this, it is useful to consider
the history and design of the C. elegans GeneChip (see http://www.
affymetrix.com/support/technical/datasheets/celegans_drosophila_
datasheet.pdf). The targets for this GeneChip were designed by
Affymetrix based on more than 18,800 Sanger Center predicted
transcripts from the December 2000 genome sequence, as well as
2,300 3’ EST clusters and 300 GenBank mRNAs (Release 121). Despite
efforts to eliminate redundancy, there is not a strict one-to-one
correspondence between the current set of genes and the probesets
on the GeneChip. Our analysis indicates that 13% of the genes on the
GeneChip are represented by more than one probe. Even so, having
unc-43 CaMKII represented by seven probesets is an unusual
situation. However, only two of these probesets (193459_s_at and
193463_s_at) are annotated as corresponding to the unc-43 CaMKII
mRNA transcript according to annotations of the C. elegans GeneChip
provided by Affymetrix in the March 28, 2003, update (downloadable
at http://www.affymetrix.com). During our examination of the eight
candidate probesets that showed decreased expression and were on
Chromosome 4, we discovered ﬁve additional probesets that
corresponded to unc-43 CaMKII. Four of these probesets
(172058_x_at, 175820_s_at, 175821_s_at, and 175824_s_at)
were based on GenBank sequences, and one (187759_s_at) was
based on a predicted open reading frame, Y43C5B.1, that was part of
the genome as of December 2000 but has since been shown to
correspond to the 59 UTR of unc-43 CaMKII. These additional
probesets provided a serendipitous blind control, since we were not
aware of their existence until they appeared on our candidate list
from the hybridization. There is also an additional (eighth) probeset
(173423_at) described in the Affymetrix annotation as correspond-
ing to unc-43 CaMKII. However, based on the current gene model,
173423_at aligns to the intron between exons 11 and 12. As would be
expected, this probeset shows no detectable expression and thus was
not considered in our analysis of the unc-43 CaMKII mutant.
Found at DOI: 10.1371/journal.pgen.0010002.sg001 (33 KB PDF).
Figure S2. Alignment of TOM-1 to Human and Rat Tomosyn
Sequences of human and mouse tomosyn were downloaded from
Ensembl (http://www.ensembl.org). The multiple sequence alignment
was performed using T-Coffee (http://www.ch.embnet.org/software/
TCoffee.html). Alignment output was produced using GeneDoc
(http://www.psc.edu/biomed/genedoc).
Found at DOI: 10.1371/journal.pgen.0010002.sg002 (104 KB PDF).
Table S1. List of Missense and Nonsense Alleles
Found at DOI: 10.1371/journal.pgen.0010002.st001 (51 KB PDF).
Accession Numbers
The National Center for Biotechnology Information Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) accession number
for the data generated by the authors and discussed in this
publication is GSE2210. The GEO accession numbers for datasets
downloaded by the authors and discussed in this paper are mdx mouse
(GDS236), mdx mutant (GDS236), PMR4 Arabidopsis (GDS417), and
PMR4 mutant (GDS417).
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession
numbers for genes and gene products discussed in this paper are
tom-1(ok285) (AY912103) and tomosyn (AY912102).
The Ensembl (http://www.ensembl.org/) accession numbers for
genes and gene products discussed in this paper are human tomosyn
(ENSP00000179882) and mouse tomosyn (ENSRNOP00000018806).
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